Adalat CC and Orkambi (Lumacaftor and Ivacaftor Tablets)
Determining the interaction of Adalat CC and Orkambi (Lumacaftor and Ivacaftor Tablets) and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of calcium channel blockers, the majority of which are primarily metabolized by the isoenzyme. Undetectable plasma levels have been reported for some calcium blockers when given orally. MANAGEMENT: Concomitant use of calcium channel blockers with potent CYP450 3A4 inducers should generally be avoided. However, if concomitant use is necessary, dosage adjustments as well as close monitoring of pharmacologic effects, particularly blood pressure, should be considered whenever a potent CYP450 3A4 inducer is added to or withdrawn from therapy. References "Product Information. Rifadin (rifampin)." Hoechst Marion-Roussel Inc, Kansas City, MO. "Product Information. Mycobutin (rifabutin)." Pharmacia and Upjohn, Kalamazoo, MI. Tada Y, Tsuda Y, Otsuka T, et al "Case report: nifedipine-rifampicin interaction attenuates the effect on blood pressure in a patient with essential hypertension." Am J Med Sci 303 (1992): 25-7
Professional:GENERALLY AVOID: Potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of calcium channel blockers, the majority of which are primarily metabolized by the isoenzyme. Undetectable plasma levels have been reported for some calcium blockers when given orally.
MANAGEMENT: Concomitant use of calcium channel blockers with potent CYP450 3A4 inducers should generally be avoided. However, if concomitant use is necessary, dosage adjustments as well as close monitoring of pharmacologic effects, particularly blood pressure, should be considered whenever a potent CYP450 3A4 inducer is added to or withdrawn from therapy.
- "Product Information. Rifadin (rifampin)." Hoechst Marion-Roussel Inc, Kansas City, MO.
- "Product Information. Mycobutin (rifabutin)." Pharmacia and Upjohn, Kalamazoo, MI.
- Tada Y, Tsuda Y, Otsuka T, et al "Case report: nifedipine-rifampicin interaction attenuates the effect on blood pressure in a patient with essential hypertension." Am J Med Sci 303 (1992): 25-7
Generic Name: nifedipine
Brand name: Adalat CC, Afeditab CR, Nifediac CC, Nifedical XL, Procardia, Procardia XL, Adalat
Synonyms: n.a.
Generic Name: ivacaftor / lumacaftor
Brand name: Orkambi
Synonyms: Orkambi
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Adalat CC-Orlistat
- Adalat CC-Ornex
- Adalat CC-Ornex Maximum Strength
- Adalat CC-Orphacol
- Adalat CC-Orphenadrine
- Adalat CC-Orphenadrine Citrate
- Orkambi (Lumacaftor and Ivacaftor Tablets)-Adalimumab
- Orkambi (Lumacaftor and Ivacaftor Tablets)-Adalimumab Prefilled Pens and Syringes
- Orkambi (Lumacaftor and Ivacaftor Tablets)-Adalimumab Subcutaneous
- Orkambi (Lumacaftor and Ivacaftor Tablets)-Adalimumab Vials
- Orkambi (Lumacaftor and Ivacaftor Tablets)-Adalimumab-adbm Subcutaneous
- Orkambi (Lumacaftor and Ivacaftor Tablets)-Adalimumab-atto Subcutaneous